Oak Harvest Investment Services Lowers Stock Position in Eli Lilly and Company (NYSE:LLY)

Oak Harvest Investment Services lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 10.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,151 shares of the company’s stock after selling 504 shares during the quarter. Oak Harvest Investment Services’ holdings in Eli Lilly and Company were worth $3,229,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in LLY. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $26,000. Core Wealth Advisors Inc. raised its position in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the last quarter. Tidemark LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $29,000. Redmont Wealth Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $40,000. Finally, Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $37,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.9 %

Eli Lilly and Company stock traded down $8.61 during mid-day trading on Thursday, reaching $898.10. The company’s stock had a trading volume of 3,078,367 shares, compared to its average volume of 2,667,176. The company has a market capitalization of $853.56 billion, a price-to-earnings ratio of 132.27, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $918.50. The business’s 50 day simple moving average is $824.60 and its 200 day simple moving average is $746.69. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.62 earnings per share. As a group, research analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on LLY shares. Truist Financial reiterated a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. BMO Capital Markets restated an “outperform” rating and set a $1,001.00 price objective on shares of Eli Lilly and Company in a report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $812.72.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 8,848 shares of the stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the sale, the insider now owns 97,299,772 shares of the company’s stock, valued at approximately $89,059,454,309.32. The disclosure for this sale can be found here. Insiders sold a total of 858,742 shares of company stock worth $735,573,781 over the last quarter. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.